DOP1B and Alzheimer disease: When TGen cohort consisting of 728 cases and 438 controls was used to validate the results from NIALOAD/NCRAD and ADNI, CNVs in AD candidate genes, including a number of previously reported regions (CHRFAM7A, RELN, and DOPEY2) as well as a new gene (HLA-DRA), were identified (Table 1; Swaminathan et al., 2012a).